Prolong Pharmaceuticals, Inc. – Trademark Portfolio
Entity Type: 03
Prolong Pharmaceuticals, Inc. owns a portfolio of 9 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), including well-known marks such as P P, EPEG, and PROLONG PHARMACEUTICALS. Of these, 3 are registered. The portfolio spans 3 Nice Classification classes, led by Class 5 (Pharmaceuticals) and Class 40 (Treatment & Processing). Headquartered in Monmouth Junction, NJ.
7 Deer Park Drive; Suite F
Monmouth Junction, NJ 08852
Showing of trademarks Trademarks
Trademark Classifications
Prolong Pharmaceuticals, Inc.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does Prolong Pharmaceuticals, Inc. have?
Prolong Pharmaceuticals, Inc. has 9 U.S. trademarks filed with the USPTO. Of these, 3 registered, 4 abandoned, 2 cancelled.
What trademark classes does Prolong Pharmaceuticals, Inc. file in?
Prolong Pharmaceuticals, Inc. files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Prolong Pharmaceuticals, Inc.'s most well-known trademarks?
Prolong Pharmaceuticals, Inc.'s registered trademark portfolio includes well-known marks such as P P, EPEG, and PROLONG PHARMACEUTICALS. These are among 3 currently registered trademarks in the portfolio.
What is Prolong Pharmaceuticals, Inc.'s trademark registration success rate?
Prolong Pharmaceuticals, Inc. has a 33% trademark registration rate, with 3 out of 9 resolved applications resulting in successful registration. Currently, 0 applications are pending review.